Mangalam Drugs And Organics Ltd.

NSE: MANGALAM BSE: 532637 SECTOR: Pharmaceuticals & Drugs  17k   52   5

105.15
+0.35 (0.33%)
NSE: Today, 03:56 PM

Price Summary

Today's High

₹ 106.3

Today's Low

₹ 104.75

52 Week High

₹ 173

52 Week Low

₹ 95.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

166.43 Cr.

Enterprise Value

243.29 Cr.

No. of Shares

1.58 Cr.

P/E

131.04

P/B

1.1

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  96

CASH

1.95 Cr.

DEBT

78.81 Cr.

Promoter Holding

50.32 %

EPS (TTM)

₹  0.8

Sales Growth

17.25%

ROE

13.97 %

ROCE

18.34%

Profit Growth

-29.72 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year17.25%
3 Year25.61%
5 Year8.29%

Profit Growth

1 Year-29.72%
3 Year64.11%
5 Year-2.47%

ROE%

1 Year13.97%
3 Year15.36%
5 Year11.8%

ROCE %

1 Year18.34%
3 Year19%
5 Year16.82%

Debt/Equity

0.5235

Price to Cash Flow

6.47

Interest Cover Ratio

3.48461283473244

CFO/PAT (5 Yr. Avg.)

1.92021665286383

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 50.32 20.93
Dec 2022 50.32 16.65
Sep 2022 50.42 16.22
Jun 2022 50.42 16.97
Mar 2022 50.53 19.98
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 25.6132163538754% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 53.5772464154885 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.92021665286383.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.92772650489922.

 Limitations

  • Promoter pledging is high as 20.93%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 120.96 109.5 108.33 63.33 91.11
Total Expenditure 110.76 99.12 99.89 56.86 90.87
Operating Profit 10.2 10.38 8.43 6.47 0.24
Other Income 0 0.01 0 0.14 0.29
Interest 2.53 3.55 2.56 3.22 3.43
Depreciation 2.69 2.6 2.76 2.88 2.75
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.98 4.24 3.12 0.5 -5.65
Tax -1.71 1.23 0.9 0.08 -1.26
Profit After Tax 6.69 3.01 2.23 0.43 -4.39
Adjusted EPS (Rs) 4.23 1.9 1.41 0.27 -2.77

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 279.38 227.58 282.35 384.7 451.07
Total Expenditure 232.53 217.9 258.66 326.68 402.01
Operating Profit 46.85 9.68 23.69 58.02 49.05
Other Income 0.84 0.32 1.18 0 0.09
Interest 11.78 8.65 10.4 9.33 11.16
Depreciation 6.57 7.09 8.22 9.18 10.25
Exceptional Items 0 0 0 0 0
Profit Before Tax 29.35 -5.74 6.25 39.52 27.73
Tax 9.46 2.29 -2 11.55 8.08
Net Profit 19.89 -8.12 8.25 27.97 19.66
Adjusted EPS (Rs.) 12.57 -5.07 5.21 17.67 12.42

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 15.83 15.83 15.83 15.83 15.83
Total Reserves 87.94 79.83 88.11 114.96 134.73
Borrowings 11.15 8.6 4.17 6.88 25.1
Other N/C liabilities 12.03 16.28 13.09 17.37 22.65
Current liabilities 99.84 90.81 109.47 109.08 130.11
Total Liabilities 226.79 211.36 230.67 264.11 328.43
Assets
Net Block 101.91 103.49 101.07 117.82 134.96
Capital WIP 0.07 0.2 1.24 4.87 0.18
Intangible WIP 0 0 0 1.48 5.53
Investments 0.24 0.24 0.22 0.22 0
Loans & Advances 1.73 2.38 8.96 5.79 5.28
Other N/C Assets 0 0 0 0 0
Current Assets 122.84 105.04 119.17 133.92 182.47
Total Assets 226.79 211.36 230.67 264.11 328.43
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 29.35 -5.74 6.25 39.52 27.73
Adjustment 18.3 16.22 18.71 17.24 22.37
Changes in Assets & Liabilities -16.81 11.21 5.64 -19.94 -15.59
Tax Paid -6.26 0 -0.05 -9.27 -8.81
Operating Cash Flow 24.58 21.69 30.55 27.55 25.71
Investing Cash Flow -15.95 -9.26 -6.87 -31.29 -27.33
Financing Cash Flow -8.82 -11.43 -23.48 2.7 2.98
Net Cash Flow -0.2 1 0.2 -1.04 1.36

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 50.53 50.42 50.42 50.32 50.32
shri jb pharma llp 16.74 16.74 16.74 16.74 16.74
shri j b pharma llp - - - - -
shree kishoriju tr... - - 6.94 - 6.94
shree kishoriju tr... - - - 6.94 -
shree kishoriju tr... 6.94 6.94 - - -
shree kishoriju tr... - - - - -
shree rasbihari tr... 6.39 6.39 - - -
shree rasbihari tr... - - - 6.39 -
shree rasbihari tr... - - - - -
shree rasbihari tr... - - 6.39 - 6.39
govardhan murlidha... 0.98 - 0.98 0.98 4.21
brijmohan murlidha... 0.49 - 0.49 0.49 3.57
dhoot govardhan mu... - 3.23 - 3.23 -
dhoot goverdhan mu... 3.23 - 3.23 - -
dhoot brijmohan mu... 3.08 3.08 3.08 3.08 -
chandrakanta murli... 2.72 2.66 2.66 - -
shweta govardhan d... - - - 2.59 2.59
smita a. dhoot 1.85 1.85 1.85 1.85 1.85
radhika a. dhoot - - - - 1.85
radhika a dhoot 1.85 1.85 1.85 1.85 -
smita a. dhoot - - - - -
rajkumari r. dhoot 1.74 1.74 1.74 1.74 1.74
raj exports privat... - - 1.21 1.21 1.21
raj exports pvt ltd 1.21 1.21 - - -
govardhan murlidha... - - - - -
govardhan murlidha... - 0.98 - - -
dhoot rekha govard... - - - 0.94 0.94
dhoot rekha goverd... 0.94 0.94 0.94 - -
ajay r dhoot - - - - -
ajay r dhoot 0.88 0.88 0.88 0.88 0.88
dhoot jyoti brijmo... 0.66 0.66 0.66 0.66 0.66
aditya r. dhoot 0.56 0.56 0.56 0.56 0.56
brijmohan murlidha... - 0.49 - - -
rajkamal sukhani 0.15 0.15 0.15 0.18 0.18
shweta goverdhan d... 0.12 0.06 0.06 - -
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 49.47 49.58 49.58 49.68 49.68
ashutosh taparia 1.91 1.91 1.91 1.91 1.91
ajay upadhyaya 1.26 1.90 1.90 1.90 1.90
sanjeevkumar tapa... 1.90 - - - -
jyotiprasad tapar... 1.19 1.33 1.33 1.33 1.33
ambika food indust... 1.04 1.04 1.04 1.04 1.04
llp 0.19 0.20 - 0.21 0.21

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Mangalam Drugs&Org. - Quaterly Results30 May 2023, 6:56PM Mangalam Drugs & Organics informs about proceeds of postal ballot2 May 2023, 4:55PM Mangalam Drugs & Organics informs about disclosure 24 Mar 2023, 10:54AM Mangalam Drugs & Organics informs about disclosure21 Mar 2023, 5:18PM Mangalam Drugs&Org. - Quaterly Results13 Feb 2023, 7:06PM Mangalam Drugs & Organics informs about disclosures 3 Dec 2022, 12:11PM Mangalam Drugs & Organics informs about disclosure26 Aug 2022, 10:13AM Mangalam Drugs & Organics informs about disclosure 23 Aug 2022, 10:08AM Mangalam Drugs & Organics informs about disclosures 19 Aug 2022, 3:51PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs & Organics informs about disclosures 2 Jul 2022, 4:48PM Mangalam Drugs & Organics informs about disclosure4 Jun 2022, 10:34AM Mangalam Drugs & Organics informs about compliance certificate8 Apr 2022, 3:47PM Mangalam Drugs & Organics informs about closure of trading window28 Mar 2022, 5:13PM Mangalam Drugs & Organics informs about disclosure5 Mar 2022, 3:43PM Mangalam Drugs & Organics informs about disclosure2 Mar 2022, 5:12PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs & Organics informs about board meeting4 Aug 2021, 3:42PM Mangalam Drugs & Organics informs about disclosure3 Aug 2021, 10:16AM Mangalam Drugs and Organics commissioning new intermediate manufacturing facility at Gujarat18 Jun 2021, 3:44PM Mangalam Drugs & Organics informs about disclosure of related party transactions11 Jun 2021, 4:53PM Mangalam Drugs and Organics gets CEP for Hydroxychloroquine Sulphate20 May 2020, 10:48AM

Mangalam Drugs&Org. Stock Price Analysis and Quick Research Report. Is Mangalam Drugs&Org. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mangalam Drugs&Org. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 25.7091 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mangalam Drugs&Org. has a Debt to Equity ratio of 0.5235 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mangalam Drugs&Org. , the EPS growth was -29.7217003553725 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mangalam Drugs&Org. has OPM of 10.8751996647959 % which is a bad sign for profitability.
     
  • ROE: Mangalam Drugs&Org. have a average ROE of 13.9738224082318 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Mangalam Drugs&Org.

X